Could Viking Therapeutics Become the Next Eli Lilly?
The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly‘s (LLY 2.28%) Zepbound delivering transformative patient results and […]
Therapeutics
Featured
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock Source link
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
Explore the exciting world of Axsome Therapeutics (NASDAQ: AXSM) with our expert analysts in this Motley Fool Scoreboard episode. Check
Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now
We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going
Why Edgewise Therapeutics Stock Popped This Week
On Thursday, an analyst launched coverage of Edgewise Therapeutics (EWTX 1.56%) stock, and the market took notice in a good
TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
Austin, Texas, United States, May 1st, 2025, FinanceWire TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial
8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%
Cathie Wood’s Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14% Cathie Wood is back in
Featured
ROSEN, A LEADING LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
ROSEN, A LEADING LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
Featured
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics Source link